Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2022-03-17 Regulatory Filings
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 87% confidence The document is a press release announcing that clinical data for the therapeutic candidate MaaT013 will be presented at the 48th EBMT Annual Meeting. It details the content of the presentation (clinical results, trial names, dates, and times) but is not the full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy statement. Since it is an announcement about the presentation of scientific/clinical data, it most closely aligns with a general corporate announcement. Given the options, it is not a specific financial report, management change, or dividend notice. It is an announcement regarding company activity, but not a formal regulatory filing (RNS) or a specific investor presentation (IP) in the sense of a deck being attached. However, because it is a formal announcement detailing upcoming presentation of results, it functions as a general corporate update. Since there is no specific category for 'Clinical Data Presentation Announcement,' and it is not a full Investor Presentation (IP) deck, the most appropriate general category for corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for press releases about corporate events, especially in a non-US context where specific SEC forms are not used. Alternatively, it could be seen as an Investor Presentation (IP) if the announcement implies the content is the core focus for investors, but RNS is safer for a press release format.
2022-03-17 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 95% confidence The document is a press release from MaaT Pharma announcing that clinical data for their drug candidate MaaT013 will be presented at the 48th annual meeting of the EBMT (European Society for Blood and Marrow Transplantation). It details the content of the presentation (clinical results, patient numbers, trial names like HERACLES) and provides logistical information about the presentation session (date, time, abstract number). This type of announcement, which publicizes the upcoming presentation of results or data at a conference, fits best under the category of an 'Earnings Release' (ER) if it were summarizing financial results, or more generally, a 'Report Publication Announcement' (RPA) if it is announcing the release/presentation of specific data/results, or potentially 'Regulatory Filings' (RNS) if it's a general corporate update. Since it is specifically announcing the presentation of clinical data at a major medical conference, and it is not the full clinical study report itself, nor a standard earnings release, the most fitting category among the provided options that covers the announcement of specific corporate/scientific updates is often the 'Report Publication Announcement' (RPA), as it announces the publication/presentation of data. However, given the context of biotech/pharma, these announcements often serve as key investor updates, similar to an ER but focused on clinical milestones. Since it is a formal press release detailing upcoming data presentation, and not a full financial report (10-K, IR) or a transcript (CT), RPA is the most precise fit for announcing the 'publication' of data at a meeting. If the document contained the actual detailed financial results, it would be ER or IR. As it is an announcement of data presentation, RPA is chosen.
2022-03-17 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma publie sa position de trésorerie et son chiffre d'affaires pour l'exercice 2021" (MaaT Pharma publishes its cash position and revenue for the 2021 fiscal year). It provides key financial highlights (cash position as of Dec 31, 2021, and 2021 revenue) immediately upon release, dated February 28, 2022. This format—a brief announcement of key period-end results without the full detail of an Annual Report (10-K) or a comprehensive Interim Report (IR)—is characteristic of an Earnings Release (ER). Although it mentions the upcoming 'Résultats annuels 2021' (Annual Results 2021) on April 15, 2022, this specific document serves as the initial, high-level announcement of the period's financial performance. FY 2021
2022-02-28 French
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document is a press release dated February 28, 2022, reporting the company's cash position and revenues for the full year 2021. It explicitly states: "today reported its cash position as of December 31, 2021, and its full-year 2021 revenues." This content structure—key financial highlights for a period (full year) released before the comprehensive report—is characteristic of an Earnings Release (ER). Although it mentions the 'Annual results 2021' are due on April 15, 2022, this document itself is the preliminary announcement of those results/highlights, not the full 10-K or the announcement of the full report (RPA). It is not a transcript (CT), a management discussion (MDA), or a full interim report (IR). FY 2021
2022-02-28 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of January 31, 2022. This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement in France, often related to capital structure updates or major shareholding notifications, but the core content is a formal count of shares/votes. While it relates to capital structure (CAP) or major shareholding (MRQ), the most precise fit for a formal, periodic disclosure of the total number of shares and voting rights, especially when mandated by securities regulators (AMF), is often categorized under general regulatory updates or specific capital structure changes. Given the options, this is a formal notification about the composition of the share capital and voting rights, which is a specific type of capital/financing update or a mandatory disclosure. Since it is a formal, periodic disclosure of the total share count, it aligns closely with updates on capital structure. However, none of the codes perfectly match a 'Total Voting Rights Disclosure'. Comparing the definitions, 'CAP' (Capital/Financing Update) is plausible, but 'MRQ' (Major Shareholding Notification) is usually for changes crossing thresholds, not the total count. 'RPA' is for announcing a report, which this is not. 'RNS' (Regulatory Filings) is the best fallback for mandatory, non-standardized regulatory disclosures. Given the highly specific nature of the content (total voting rights disclosure), and lacking a dedicated code, I will classify it as a general Regulatory Filing (RNS), as it is a mandatory disclosure to the market via the regulator (AMF). If a more specific code existed for 'Total Voting Rights', that would be chosen. Based on the provided list, RNS is the most appropriate catch-all for this mandatory regulatory update that doesn't fit the other specific financial report types.
2022-02-09 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 8, 2022, announcing a partnership between MaaT Pharma and Skyepharma to build a bioproduction facility. The content focuses on strategic business development, capacity expansion, and future production plans for drug candidates (MaaT013, MaaT033). This type of announcement, detailing strategic agreements, financing implications (though specific terms are confidential), and operational expansion, most closely aligns with a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it details a major operational and strategic agreement concerning future production capacity and partnership terms, it fits best under 'Capital/Financing Update' (CAP) as it directly impacts the company's capital structure/operational capacity, or potentially 'Regulatory Filings' (RNS) if it's a general market disclosure. Given the focus on building a major asset and securing production capacity to support commercial launch, 'CAP' is a strong candidate, but 'RNS' is often used for general press releases about strategic deals that aren't strictly financial reports or earnings. Since the core subject is a major business agreement impacting future operations and potential financing needs/structure, and it is not a standard financial report (10-K, IR, ER), 'RNS' (Regulatory Filings/General Announcement) is the safest classification for a non-standard press release detailing a strategic partnership, especially in the context of European filings where specific US SEC codes don't apply directly. Given the options, and that it's a general announcement of a significant business event, RNS is appropriate as a broad regulatory/market disclosure category.
2022-02-08 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.